Filing Flows › International Stem Cell (ISCO) › Q2 2026 › vs Q2 2025
International Stem Cell (ISCO) Q2 2026 vs Q2 2025 (year over year)
International Stem Cell's revenue rose $228K (+9%) from $2.4M in Q2 2025 to $2.7M in Q2 2026. The biggest changes: Biomedical Market +$221K (+10%); Anti Aging Skincare Market +$7K (+5%).
International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%, net loss $71K, operating cash flow $167K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.0% | -13.6% | +19.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Biomedical Market | $2.5M | $2.3M | $221K | +10% |
| Anti Aging Skincare Market | $151K | $144K | $7K | +5% |
| Revenue | $2.7M | $2.4M | $228K | +9% |
| Net loss | $71K | −$129K | $200K | — |
| Costs & expenses | $2.7M | $2.4M | $299K | +12% |
| Operating costs | $2.7M | $2.3M | $430K | +19% |
| Interest & other, net | $36K | $38K | −$2K | -5% |
| Cost of revenue | $1.2M | $927K | $290K | +31% |
| Research & development | $155K | $162K | −$7K | -4% |
| Sales & marketing | $276K | $286K | −$10K | -3% |
| General & admin | $1.1M | $905K | $157K | +17% |
| Operating cash sources | $238K | −$429K | $667K | — |
| Depreciation & amortization | $28K | $54K | −$26K | -48% |
| Share-based compensation | $59K | $61K | −$2K | -3% |
| Working capital & other | $151K | −$544K | $695K | — |
| Net loss absorbed | $71K | −$129K | $200K | — |
| Operating cash flow | $167K | −$300K | $467K | — |
| Free cash flow (OCF − capex) | $160K | −$332K | $492K | — |
| Capital expenditures | $7K | $32K | −$25K | -78% |
Questions
How much did International Stem Cell's revenue grow year over year in Q2 2026?
International Stem Cell's revenue rose $228K (+9%) from $2.4M in Q2 2025 to $2.7M in Q2 2026.
What drove International Stem Cell's revenue change in Q2 2026?
Biomedical Market +$221K (+10%); Anti Aging Skincare Market +$7K (+5%).